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Abstract
Background: The decline in the efficacy of artemisinin-based combination treatment (ACT) in some endemic
regions threatens the progress towards global elimination of malaria. Molecular surveillance of drug resistance in
malaria-endemic regions is vital to detect the emergence and spread of mutant strains.
Methods: We observed 89 malaria patients for the efficacy of artemether-lumefantrine for the treatment of
uncomplicated Plasmodium falciparum infections in Lagos, Nigeria and determined the prevalence of drug resistant
strains in the population. Parasite clearance rates were determined by microscopy and the highly sensitive var gene
acidic terminal sequence (varATS) polymerase chain reaction for 65 patients with samples on days 0, 1, 3, 7, 14, 21
and 28 after commencement of treatment. The genomic finger print of parasite DNA from pre- and post-treatment
samples were determined using 24 nuclear single nucleotide polymorphisms (SNP) barcode for P. falciparum. Drug
resistance associated alleles in chloroquine resistance transporter gene (crt-76), multidrug resistance genes (mdr1–86
and mdr1–184), dihydropteroate synthase (dhps-540), dihydrofolate reductase (dhfr-108) and kelch domain (K-13580)
were genotyped by high resolution melt analysis of polymerase chain reaction (PCR) fragments.
Results: By varATS qPCR, 12 (18.5%) of the participants had detectable parasite DNA in their blood three days after
treatment, while eight (12.3%) individuals presented with genotypable day 28 parasitaemia. Complexity of infection
(CoI) was 1.30 on day 0 and 1.34 on day 28, the mean expected heterozygosity (HE) values across all barcodes were
0.50 ± 0.05 and 0.56 ± 0.05 on days 0 and 28 respectively. Barcode (π) pairwise comparisons showed high genetic
relatedness of day 0 and day 28 parasite isolates in three (37.5%) of the eight individuals who presented with re-
appearing infections. Crt-76 mutant allele was present in 38 (58.5%) isolates. The mdr1–86 mutant allele was found
in 56 (86.2%) isolates. No mutation in the K-13580 was observed.
Conclusions: Persistence of DNA-detectable parasitaemia in more than 18% of cases after treatment and
indications of genetic relatedness between pre- and post-treatment infections warrants further investigation of a
larger population for signs of reduced ACT efficacy in Nigeria.
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Background
Malaria caused by Plasmodium falciparum infection is
a significant public health problem in Nigeria where
over 30% of the global burden of the disease is borne
despite recent mass scale-up of intervention measures
[1]. Artemisinin-based combination therapy (ACT) is
recommended as first line treatment against uncom-
plicated malaria and it remains a critical tool in mal-
aria control programmes. The most commonly used
ACT, Artemether-Lumefantrine (AL), remains largely
efficacious in sub-Saharan Africa [1]. The efficacy of
AL has been attributed to the fast action of artemisi-
nin and the resultant rapid reduction in the density
of asexual malaria parasites, while lumefantrine acts
to prevent recrudescence [2]. However, resistance to
artemisinin-based drugs has been reported in many
endemic regions in South-East Asia [3]. Although evi-
dence of resistance among African populations of
Plasmodium falciparum remains scarce, there have
been emerging cases of potentially adaptive strains
and slow parasite clearance following treatment [4, 5].
These parasites are often below the threshold of de-
tection and are rarely re-treated, thus contributing to
disease transmission and spread of resistance [6]. Ac-
curate detection, quantification and characterization
of such parasite isolates after treatment is necessary
for the proper evaluation and monitoring of drug
efficacy.
One recent technique for the ultra-sensitive detection
of low parasitaemia involves the amplification of the var
gene family present in the sub-telomere of the parasite
[7]. Each parasite isolate comprises about 50–150 var
genes [8], which possess acidic terminal sequence (ATS)
with well-conserved domains that are targeted. Once de-
tected, parasite isolates before and after treatment can
be genetically fingerprinted with a single nucleotide
polymorphism (SNP) barcode, which is another sensitive
assay that requires only a small amount of input DNA
and can be used to distinguish recrudescence from
re-infection [9]. Prompt detection of mutations in loci
implicated in drug resistance such as multidrug resist-
ance gene (mdr1), chloroquine resistance transporter
(crt), dihydrofolate reductase (dhfr), dihydropteroate syn-
thase (dhps) and kelch-13 (K13) genes provides molecular
evidence of antimalarial resistant parasites [10, 11]. For ac-
curate surveillance of ACT resistance in a
malaria-endemic setting as Nigeria, there is a need for
continuous therapeutic efficacy studies using sensitive
techniques that enable early detection of tolerant parasite
strains. In this study, we assessed the efficacy of
artemether-lumefantrine, determined genetic relatedness
of parasites isolated before and after treatment and the
prevalence of markers of drug resistance in the parasite
population.
Methods
Study design and sample collection
This observational study of a 28-day follow-up was con-
ducted in Ijede and Agbowa General Hospitals (GH) in
Ikorodu, a peri-urban settlement in Lagos, South-West
Nigeria, from August – November, 2016 following the
revised WHO drug efficacy protocol [12]. Ijede GH is
one of the sentinel sites used by the country’s Federal
Ministry of Health (FMoH) for antimalarial drug efficacy
trials. Individuals (1–70 years) presenting at the hospital
with symptoms of uncomplicated malaria were screened
for Plasmodium falciparum, first by rapid diagnostic test
(RDT), followed by microscopy (Olympus BX53M, UK).
The recruitment criteria included fever in the preceding
two days, no history of antimalarial intake in the previ-
ous four weeks and P. falciparum parasitaemia > 2000/μl
of blood on presentation [12]. Individuals with signs of
complicated malaria or mixed infections were censored
and those that developed concurrent ailments and com-
plications during follow-up were promptly attended to
by clinicians and hospital staff and therefore withdrawn
from the study. Confirmed cases of uncomplicated
malaria were treated with appropriate doses of AL
(Coartem, Novartis, Switzerland) according to national
policy on malaria treatment [13]. Based on an expected
maximum treatment failure rate of 5% in a related popu-
lation [14] and the desired confidence level (95%) and
precision (5%), a minimum of 73 patients were required
[12]. An additional 20% was added as provision for pa-
tients lost to follow up. Participants and/or their par-
ents/guardians were instructed on how and when to
take the evening dose. They were also advised to take
fatty meals before or after drug intake to ensure proper
absorption of the drug. Following consent, participants
were followed up on days 1, 3, 7, 14, 21 and 28
post-treatment (Fig. 1). Confirmation of drug adminis-
tration at home was done during the follow-up visits by
tablet count. Patients were advised to return on any day
during the follow-up period if symptoms returned and
not to wait for our next scheduled visit day.
The primary endpoint was clinical and parasitological
response within 28 days of commencement of treatment.
The secondary endpoint was prevalence of drug resist-
ance markers and genetic relatedness of pre- and
post-treatment infections. Participants failing treatment,
defined as the reappearance of parasitaemia after an ini-
tial complete clearance or failure of complete clearance
on day 28, were retreated with AL whether or not they
developed symptoms and after samples had been ob-
tained for microscopy and molecular analyses. Before
the first treatment was administered, dried blood spots
from finger pricks were collected from individuals who
gave informed consent and/or assent and also met the
recruitment criteria.
Oyebola et al. BMC Infectious Diseases  (2018) 18:392 Page 2 of 9
varATS qPCR assessment of antimalarial treatment
Plasmodium falciparum DNA was extracted from pre-
and post-treatment dried blood spots using the QiaAmp
DNA minikit (Qiagen, Germany). The var gene acidic
terminal sequence (varATS) quantitative PCR was used
to detect multi-copy genomic sequences of low-density
infections in follow-up samples [7]. The primer/probe
sequences and the cycling conditions are described in
Additional file 1: Table S1. Briefly, 1 μl of PCR water,
10 μl of 2× Taqman Universal PCR Mastermix (Applied
Biosystems, New Jersey, USA), 1.6 μl of 10uM forward
and reverse primers, 0.8 μl of 10 μM probe and 5 μl of
parasite DNA were vortexed and run on CFX 96 Touch™
Real-Time System (Bio-Rad Laboratories, CA, USA).
Genotyping of antimalarial drug resistance SNPs
The prevalence of antimalarial drug resistance
markers was determined using High Resolution Melt
analysis of PCR fragments and probes targeting SNPs
[15]. Six SNPs marking variant codons for antimalarial
drug resistance were analysed: Chloroquine resistance
transporter (crt-76), multidrug resistance (mdr1–86 and
mdr1–184), dihydropteroate synthase (dhps-540), dihy-
drofolate reductase (dhfr-108) and Kelch-13 (K-13580),
(see Additional file 1: Table S2 for primer sequences and
reaction conditions). Individual samples were traced
through time points and the phenotype-genotype as-
sociations were profiled for day 0 and day 28 para-
sites. SNPs were genotyped for all samples positive
for parasite DNA by PCR before treatment and on
follow-up days.
Molecular SNP barcoding
Molecular fingerprinting and changes in infection com-
plexity before and after drug application was determined
by SNP barcode assay. Day 0 and 28 parasitaemia bar-
codes were compared to determine if there was failure
to clear the original parasites by the drug (recrudes-
cence) or re-infection by other parasite strains. A panel
of twenty-four unlinked neutral SNP barcodes with
minor allele frequencies (MAF) ranging between 0.2–0.5
and representatively spread across the parasite genome
(Additional file 1: Table S3) were used. Assays were per-
formed as described by Daniels et al. [9], using the same
primer and probe sequences. For pre- and post-treatment
parasites, pairwise analysis, barcodes with a mixed allele
call for more than one locus were considered as polyge-
nomic and omitted from the analysis. Samples missing al-
lele calls for more than five SNPs were also eliminated
from the analysis.
Data and genetic analyses
GraphPad Prism 7 (CA, USA) software was used for
statistical analyses. Parasite clearance rates were deter-
mined by the Parasite Clearance Estimator (PCE) tool
(http://www.wwarn.org). The varATS qPCR survival es-
timates of parasites at different time-points were deter-
mined using Kaplan-Meier survival analysis. Association
between age and parasite counts on days 0, 3 and 28
was assessed using Spearman’s correlation coefficient
(rs). The relationships between enrollment parasite dens-
ity on day 0 and parasitaemia on days 3 and 28 were also
determined using Spearman’s correlation coefficient.
Bonferroni correction was used to adjust multiple testing
Single-arm prospective follow-up on days 0,1,3,7,14,21 
and 28 following ACT treatment
561 participants screened for malaria
Tested positive for P. falciparum = 150
Inclusion = 89
Good quality samples and 
complete information for 
downstream analyses = 65
Diagnosis
Microscopy
varATS
High 
resolution 
melt 
analysis for 
drug 
resistance 
typing
Molecular 
SNP 
barcoding
Data and genetic 
analysis
Exclusion = 61
Fig. 1 Study flow chart
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of age and parasitaemia on days 0, 3 and 28. To determine
the genetic identity of each pair of samples on day 0 and
day 28, we calculated pairwise barcode similarity index
(π), counting ambiguous or missing calls as mismatches
[16]. To avoid biasing the percent similarity because of
matching major alleles, we limited the percent similarity
calculations to include only sites where the minor alleles
were present in pairwise barcodes of day 0 and day 28 iso-
lates. The similarity index, π, was calculated as the num-
ber of sites where the minor allele matched divided by the
total number of sites where the minor allele was present.
π has a potential range from 0 (no genetic relatedness) to
1(high genetic relatedness). The allele frequencies per
SNP barcode, allelic diversity in pre-treatment and day 28
parasite populations and allele frequencies per barcode
per population were calculated using GENALEX 6 [17].
Complexity of infection per SNP barcode was estimated
using COIL [18]. Allelic diversity was calculated for each
of SNP barcodes based on the allele frequencies, using the
formula Nei’s unbiased genetic diversity index for ex-
pected heterozygosity, HE = [ ð nn−1Þð1−
P
P2Þ , where n is
the number of isolates analyzed and P represents the fre-
quency of each allele of the SNP. HE provides an indica-
tion of the probability that two samples will be different. It
has a potential range from 0 (no allele diversity) to 1 (high
allelic diversity). All statistical assumptions were made at
95% confidence limit.
Results
Baseline information on the study participants
In this study, 561 individuals were screened, 150 of them
tested positive for falciparum malaria. Eighty-nine pa-
tients met the inclusion criteria, were enrolled and
followed up. Sixty-five participants had complete sample
information for days 1, 3, 7, 14, 21 and 28 after com-
mencement of treatment and were used for genetic ana-
lyses. The demographic profiles of the participants are
presented in Table 1. Participants were stratified into
three age groups: 1-5 yrs.; 6–14 years and ≥ 15 years old
(Table 1).
Parasite clearance rates
Microscopic analysis showed that none of the partici-
pants presented with parasitaemia on day 3 while one of
the participants presented with parasitaemia on day 28
(Fig. 2). Based on the detection of parasite DNA in per-
ipheral blood by varATS PCR assay, four main parasite
clearance profiles could be identified (Fig. 3): Group A-
individuals who cleared infection by day 1, (ii) Group
B-those who remained positive until day 3, Group
C-individuals who remained positive until day 7, and
Group D-those who tested positive beyond day 7. var-
ATS results showed that 12 (18.5%) of participants pre-
sented with parasitaemia 3 days post-treatment while
eight (12.3%) patients presented with genotypable day 28
parasitaemia (Fig. 4).
Relationship between enrolment parasite density and
post-treatment parasitaemia
The relationship between parasite persistence after treat-
ment and the levels of parasitaemia at enrolment was
examined by varATS qPCR using Spearman’s correlation
coefficient (rs). There was no linear association (P = 0.79)
between the starting parasite density and day 3 parasit-
aemia. Similarly, there was no correlation (P = 0.69) be-
tween the enrolment parasitaemia and day 28 parasite
count. There was a weak linear association between
parasite densities on day 3 and reappearance on day 28
(rs = 0.12) even though the relationship was not statisti-
cally significant (P = 0.33). Analysis of parasitaemia and
patient characteristics (Table 2) did not indicate any re-
lationship between age of the participant and parasite
density on day 0 (P = 0.25). There was a weak inverse as-
sociation between the age of patients and (i) persistence
of parasitaemia on day 3 (rs = − 0.24; P = 0.056) and (ii)
re-appearance of parasitaemia on day 28 (rs = − 0.41; P =
0.0008). After adjusting for multiple testing using Bon-
ferroni method and with a new cut-off of 0.0167 for the
tests between age and days 0, 3 and 28 parasitaemia, we
observed an inverse relationship between parasitaemia
on day 28 and age of the patient. None of the patients
with positive parasitaemia post-treatment reported with
clinical symptoms of malaria.
Genetic description of day 0 and day 28 parasite
populations
Allele frequencies at each of the barcodes in the day 0
and day 28 populations are presented in Additional file 2:
Datasheet S1. The complexity of infection in the day 0
Table 1 Summary of participant characteristics at baseline
Characteristic Number screened n (%) Number positive for P. falciparum n (%) Number enrolled n (%)
Sex Male 157 (27.99) 19 (12.67) 18 (27.69)
Female 404 (72.01) 131 (87.37) 47 (72.31)
Age group 1–5 years 138 (24.60) 22 (14.67) 13 (20.0)
6–14 years 80 (14.26) 12 (8.0) 21 (32.31)
≥15 years 343 (61.14) 116 (77.33) 31 (47.69)
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population was 1.30 while the CoI on day 28 marginally in-
creased to 1.34 on day 28 (Additional file 2: Datasheet S2),
however, this difference was not statistically significant (P =
0.42). The mean HE values across all barcodes on day 0 was
0.50 ± 0.05 and 0.56 ± 0.05 on day 28. There was no evi-
dence of significant linkage disequilibrium (Additional
file 1: Table S4), although the ISA value was higher in
day 0 (0.08) than in day 28 populations (0.03).
Signatures of relatedness between individual pre- and
post-treatment infections
We used the analysis of barcode sequence identity to
estimate relatedness between pairwise parasite isolates
in day 0 and day 28 infections (Additional file 2:
Datasheet S3). The barcode (π) pairwise comparisons
showed high genetic relatedness of day 0 and
re-appearing day 28 parasite isolates in three (37.5%)
of the eight participants who presented with day 28
parasitaemia (Table 3).
Prevalence of drug resistance polymorphisms
When the pre-treatment parasites were taken to-
gether, the crt-76 T mutant allele was present in 38
(58.5%) isolates. The mdr1–86 mutant allele was
found in 56 (86.2%) of isolates. We observed 94.4%
mutant and 5.6% wildtype alleles of Dhps-540 and
100% mutant alleles of Dhfr-108 in the population.
No mutant allele of the K-13 C580Y was observed
(Fig. 5). Pairwise phenotype-genotype comparisons
showed no association of mdr1 (N86Y and Y184F)
and crt K76 T mutations with persistence of parasit-
aemia on day 3 (Table 4) and re-appearance on day 28
(Table 5).
Discussion
One of the key approaches to malaria control is prompt
treatment of patients for an improvement in health and
prevention of onward transmission. With rising reports of
drug-resistant Plasmodium falciparum, surveillance of
ACT efficacy becomes important so that recrudescent in-
fections can be promptly detected, treated and docu-
mented. In this study, we reported in vivo re-appearance
of parasites following appropriate treatment of uncompli-
cated P. falciparum with artemether-lumefantrine in
Nigeria. The genomic barcode analysis of pre-treatment
and re-appearing infections suggested recrudescence
Fig. 2 Parasite count/μl by microscopy before and after artemether/
lumefantrine treatment. (After day 1, the mean concentration was the
same up to day 14 with re-appearing infections on days 21 and 28)
Fig. 3 Kaplan-Meier estimates of parasite reduction following
artemether-lumefantrine treatment (Group A represents %
reduction of parasitaemia on day 1, (ii) Group B represents %
reduction of parasitaemia on day 3, Group C represents %
reduction of parasitaemia on day 7, and Group D represents %
parasitaemia beyond day 7
Fig. 4 Log10 Parasite count/μl by varATS qPCR before and after
artemether/lumefantrine treatment (Low-grade residual infections
persist on days 1, 3, 7, 4 and 28)
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despite the absence of mutation in K-13 C580Y. This sug-
gests that the potency of the most promising antimalarial
drug, artemisinin-based combination, in treating P. falcip-
arum infection in Nigeria may be progressively waning.
High genetic diversity of the parasites was observed in
the population. This observation is in line with expecta-
tions from high transmission settings where multiple
parasite genomes in each sample and highly variable
combinations of barcodes among individuals in the
population have been observed [19]. We also observed a
marginal increase in CoI 28 days after treatment sug-
gesting a possible lack of clonal expansion following
treatment. This agrees with the observation in Kenya
where, contrary to expectations of reduced CoIs caused
by the persistence of only drug-resistant strains in
post-treatment infections, CoI on day 28 was higher
than day 0 [20].
Age and immunity have previously been demon-
strated as indicators of varying therapeutic responses
[21]. Thus, older individuals living in a high transmis-
sion area who have a more developed acquired im-
munity than children in the same setting would be
expected to have fewer persistent infections following
treatment. While our finding could not directly cor-
relate age with the persistence of parasitaemia on the
third day of treatment, it revealed re-appearance of
infections on day 28 only among children less than
fifteen years old. This observation possibly explains
the role of acquired immunity in complementing anti-
malarial drug action in parasite clearance. However,
additional studies are required to understand the in-
fluence of immunity on therapeutic response and
drug resistance by correlating parasite clearance rates
with malaria antibody titres in the individuals.
Although we did not observe any clinical outcome of
persistent infections and there was no direct association
between re-appearance of infection and day 0 parasite
densities, it is important to continue monitoring the
prevalence of residual infections following treatment,
even though they were observed in low quantities in this
study. Since parasitaemia as low as 0.5/μl of blood corre-
sponds to as high as approximately one million parasites
in the body [21], low-grade infections observed after
treatment in this study area may sustain a reservoir for
silent transmission of the disease. Studies that involve
longer follow-up durations and laboratory adaptation of
the sub-microscopic parasites may provide more infor-
mation on the transmission potential of these
post-treatment parasites.
A high frequency of mutant alleles of crt and mdr1
(N86Y and Y134F) was reported in this study, but these
mutations have not been directly associated with post-
treatment re-appearance of infections. In addition, con-
trary to a previous report showing that polymorphisms
in mdr1 genes were associated with decreased sensitivity
to lumefantrine [22], our phenotype-genotype associ-
ation study provided no evidence that the presence of
86Y allele sensitized parasites to lumefantrine as there
was no correlation between the distribution of N86 and
134F alleles and presence of parasites on day 28. An in-
crease in the frequency of Pfcrt 76 T is associated with
reduced sensitivity to chloroquine [23] and the removal
of drug pressure is expected to cause a decline in resist-
ance conferring mutations [24]. The prevalence of mu-
tant 76 T allele in this present investigation is lower than
previously reported before the proscription of CQ for
mild malaria treatment in Nigeria [25]. This may be a
pointer to ongoing selection for chloroquine-susceptible
parasites following widespread use of artemisinin.
Kelch-13 sequencing information from recent thera-
peutic efficacy studies conducted in Cambodia, Lao and
Vietnam has revealed cysteine to tyrosine mutation in
codon 580 of K13 gene (C580Y) as the dominant poly-
morphism associated with artemisinin resistance [3].
However, our investigation revealed the absence of this
mutation in re-appearing parasites.
Table 2 Mean (and standard deviation) of parasitaemia (by varATS) per age group
Age group Day 0 Day 1 Day 3 Day 7 Day 28
1–5 years 7,856,186.72 ± 19,107,401.41 89,555.78 ± 198,852.33 0.00172 ± 0.00433 0.00047 ± 0.00098 17,651.29 ± 59,342.22
6–14 years 5,365,728.80 ± 18,300,622.30 2640.90 ± 2553.02 0.00051 ± 0.00110 0.00057 ± 0.00035 11,157.18 ± 11,157.14
≥15 years 519,906.10 ± 1,394,260.12 3835.63 ± 1704.04 0.00340 ± 0.01810 41.50 ± 41.50 0.00015 ± 0.00079
Table 3 Age of participants and barcode similarity (π) indices of
parasites before and after drug treatment
Sample ID Age (years) aπ
IJD 244 2 0.23
IJD 254 10 0.30
IJD 095 10 0.36
IJD 393 3 0.47
AJ 008 14 0.59
IJD 203 7 0.83
IJD 253 4 0.94
AGB 002 3 1.0
aBarcode similarity index (π) close to 1 suggests high genetic relatedness
between two parasite isolates
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We propose further investigations involving complete
genome-wide associations between pre-treatment and
persistent parasites to circumvent the limitation of our
study which did not preclude the influence of
re-infection with the same parasite type or residual para-
site DNA and non-replicating mature gametocytes that
can persist at low concentrations after treatment. Compu-
tational analyses that involve the combination of genomic
information with epidemiological simulations will present
complementary tools for interpreting population-level im-
pact of drug interventions. In addition, since P. falciparum
is thought to exhibit drug-induced developmental arrest
until the activity of artemisinin in the host has diminished
[26], details about quiescence in post-treatment infections
using in vitro models may further explain the underlying
mechanisms of re-appearance of parasites after treatment
in the study area. A broader line of investigation on the ef-
ficacy of ACTs in larger populations in the country and
across the borders is necessary to understand spatial and
temporal heterogeneity of infectious reservoirs
post-treatment.
Conclusions
We have reported in vivo re-appearance of parasites fol-
lowing appropriate treatment of uncomplicated Plasmo-
dium falciparum with Artemether/Lumefantrine (AL) in
94.4
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Fig. 5 Prevalence of polymorphisms in Plasmodium falciparum drug resistance genes in pre-treatment parasite population (K13: Kelch 13 gene; Dhps:
Dihydropteroate synthase; Pfcrt: Plasmodium falciparum chloroquine resistance transporter gene; Pfmdr1: Plasmodium falciparum chloroquine resistance
transporter gene; Dhfr: Dihydrofolate reductase)
Table 4 Phenotype-genotype association of infections on day 3
Genotype n (%)
mdr1–86 mdr1–184 crt-76 K13–580
Phenotype N Y N/Y Y F Y/F K T K/T C Y C/Y
Individuals with parasites on day 3 = 12 0 (0%) 10
(83.3%)
2
(16.7%)
2
(14.3%)
8
(66.6%)
2
(16.7%)
2
(16.7%)
8(66.6%) 2
(16.7%)
12
(100%)
0
(0%)
0
(0%)
Individuals with full clearance of parasites
on day 3 = 53
5
(9.43%)
46
(86.8%)
2
(3.8%)
11
(20.8%)
29
(54.7%)
13
(24.5%)
10
(18.9
40
(75.5%)
3
(5.7%)
53
(100%)
0
(0%)
0
(0%)
N86 =mdr1–86 wildtype allele; 86Y =mdr1–86 mutant allele; Y184 =mdr1–184 wildtype allele; 184F =mdr1–184 mutant allele; K76 = crt-76 wildtype allele; 76 T =
crt-76 mutant allele; C580 = K13 wildtype allele; 580Y = K13 mutant allele
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Nigeria. The genomic barcode analysis of pre-treatment
and re-appearing infections suggested recrudescence
despite the absence of mutation in K-13 C580Y. This
finding implies that the Nigerian parasites could be
deploying a more complex drug evasion mechanism be-
yond the C580Y polymorphism. Further investigation of
a larger population of parasites in the country is re-
quired for signs of reduced efficacy of artemisinin-based
treatment of malaria.
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